Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
  • A61K8/466—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur containing sulfonic acid derivatives; Salts
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
  • A61K8/602—Glycosides, e.g. rutin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
  • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/10—Washing or bathing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q5/00—Preparations for care of the hair
  • A61Q5/02—Preparations for cleaning the hair
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/74—Biological properties of particular ingredients
  • A61K2800/75—Anti-irritant
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
  • A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine

Definitions

• the invention relates to compositions containing at least one biosurfactant and at least one sulfonic or sulfinic acid derivative and their uses.
• biosurfactants are known to have a characteristic colour and odour, which needs to be reduced, so that the biosurfactants as raw material fulfil the market’s needs.
• WO2016115048 describes process steps of deodorising and decolourising rhamnolipid compositions.
• One disadvantage of the described invention is the inclusion of an additional process step in the production of rhamnolipids.
• EP2821495 discloses a method for solving the problem to sophorolipid-containing compositions having a reduced smell by providing a high-purity acid-form sophorolipid.
• WO2013129667 addresses the problem of sophorolipids suffering of irritative odour due to fermentation by-products generated in the fermentation generation processes.
• WO2018108925 discloses sulfonic acid salt compositions useful for colour stabilization of nonliving organic matter such as from lacquers, paints, powder-coatings, and polymers in particular water-absorbent polymers. The writ states, that sulphurous reducing agents in general are of unpleasant odour, which is unwanted in the final polymer products. It is disclosed, that the disodium salt of the used sulfonic acid has a very well noticeable odour.
• Salts of multivalent metals as zinc, aluminium and magnesium of 2-xydroxy-2-sulfonatoacetate are disclosed to bear a reduced odour.
• W02004084962 discloses a colour-stable superabsorbent polymer having long-term colour stability, which is prepared using a sulfinic acid derivative, like 2-hydroxy-2-sulfinatoacetic acid, as the reducing agent in the polymerization initiator system. It is an object of the invention to provide compositions containing biosurfactants with an improved odour profile.
• R 1 selected from H and Ci - Ce alkyl
• compositions according to the instant invention have a positive odour profile.
• compositions according to the instant invention have an improved colour stability.
• Colour change reactions could come from Maillard reaction, which is a chemical reaction between proteins or amino acids and sugars. Both reaction partners, proteins and sugars, are typically contained in small amounts in a fermentative produced biosurfactant like Rhamnolipids, Sophorolipids or Rubiwettin. These small concentrations are sufficient to have a colour change from light to dark.
• a further advantage is that the compositions according to the instant invention have improved cleaning properties of surfaces.
• compositions according to the instant invention has excellent foaming properties.
• compositions according to the instant invention is their reduced irritation for human skin.
• compositions according to the instant invention is their mildness and good physiological compatibility, in particular characterized by a high value in the red blood cell (RBC) test.
• compositions according to the instant invention is their good skin feel during and after washing.
• compositions according to the instant invention is that they leave behind a smooth and soft skin feel after washing.
• compositions according to the instant invention is their outstanding microbial stability.
• compositions according to the instant invention have an improved ability to dissolve oils and fats.
• biosurfactants are understood as meaning all glycolipids produced by fermentation.
• biosurfactant also covers glycolipids that are chemically or enzymatically modified after fermentation, as long as structurally a glycolipid remains.
• Raw materials for producing the biosurfactants that can be used are carbohydrates, in particular sugars such as e.g. glucose and/or lipophilic carbon sources such as fats, oils, partial glycerides, fatty acids, fatty alcohols, long-chain saturated or unsaturated hydrocarbons.
• aqueous medium is understood as meaning a composition which comprises at least 5% by weight of water, based on the total composition under consideration.
• composition according to the instant invention preferably is an aqueous composition.
• a preferred composition according to the invention is characterized in that the pH of the mixture composition at 25°C is from 3.0 to 9, preferably from 4.0 to 7 and particularly preferably from 5.0 to 6.6.
• composition according to the instant invention preferably comprises as component A) at least one biosurfactant selected from rhamnolipids, sophorolipids, glucose lipids, cellulose lipids, mannosylerythritol lipids and trehalose lipids, preferably rhamnolipids and sophorolipids.
• biosurfactants in particular glycolipid surfactants, can be produced e.g. as in EP 0499434,
• Suitable biosurfactants can be acquired e.g. from Soliance, France.
• the composition according to the instant invention has, as biosurfactant at least one selected from rhamnolipids, in particular mono-, di- or polyrhamnolipids, glucolipids, in particular mono-, di- or polyglucolipids, and sophorolipids, in particular mono-, di- or polysophorolipids, most preferably rhamnolipids.
• rhamnolipids in particular mono-, di- or polyrhamnolipids
• glucolipids in particular mono-, di- or polyglucolipids
• sophorolipids in particular mono-, di- or polysophorolipids, most preferably rhamnolipids.
• rhamnolipids in the context of the present invention preferably is understood to mean particularly compounds of the general formula (II) and salts thereof,
• the glycosidic bond between the two rhamnose units is preferably in the a-configuration.
• the optically active carbon atoms of the fatty acids are preferably present as R-enantiomers (e.g. (R)-3- ⁇ (R)-3-[2-0-(a-L-rhamnopyranosyl)-a-L-rhamnopyranosyl]oxydecanoyl ⁇ oxydecanoate).
• R-enantiomers e.g. (R)-3- ⁇ (R)-3-[2-0-(a-L-rhamnopyranosyl)-a-L-rhamnopyranosyl]oxydecanoyl ⁇ oxydecanoate.
• Rhamnolipids applicable in the context of the instant invention can also be produced by fermentation of Pseudomonas, especially Pseudomonas aeruginosa, which are preferably non genetically modified cells, a technology already disclosed in the eighties, as documented e.g. in EP0282942 and DE4127908.
• Pseudomonas especially Pseudomonas aeruginosa
• Rhamnolipids produced in Pseudomonas aeruginosa cells which have been improved for higher rhamnolipid titres by genetical modification can also be used in the context of the instant invention; such cells have for example been disclosed by Lei et al. in Biotechnol Lett. 2020 Jun;42(6):997-1002.
• Rhamnolipids produced by Pseudomonas aeruginosa are commercially available from Jeneil Biotech Inc., e.g. under the tradename Zonix.from Logos Technologies (technology acquired by Stepan), e.g. under the tradename NatSurFac, from Biotensidion GmbH, e.g. under the tradename Rhapynal, from AGAE technologies, e.g. under the name R90, R95, R95Md, R95Dd, from Locus Bio-Energy Solutions and from Shanghai Yusheng Industry Co. Ltd., e.g. under the tradename Bio- 201 Glycolipids.
• the present invention provides a composition preferably comprising as biosurfactant rhamnolipids, characterized in that the biosurfactant component A) comprises
• composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 0.5% by weight to 15% by weight, preferably 3% by weight to 12% by weight, particularly preferably
• diRL-C10C12:1 5% by weight to 10% by weight, of diRL-C10C12:1 , where the percentages by weight refer to the sum of all of the rhamnolipids present.
• composition according to the invention is characterized in that the composition comprises as biosurfactant rhamnolipids as described above with a content of 0.1% by weight to 5% by weight, preferably 0.5% by weight to 3% by weight, particularly preferably 0.5% by weight to 2% by weight, of monoRL-C10C12 and/or, preferably and 0.1 % by weight to 5% by weight, preferably 0.5% by weight to 3% by weight, particularly preferably
• the term “sophorolipids” preferably is understood as meaning compounds of the general formulae (Ilia) and (lllb) and salts thereof formula (Ilia)
• R 1SL H or CO-CH3
• R 2SL H or CO-CH3
• R 3SL a divalent organic moiety which comprises 6 to 32 carbon atoms and which is unsubstituted or substituted by hydroxyl functions, is unbranched and optionally comprises one to three double or triple bonds,
• Sophorolipids may be used in accordance with the invention in their acid form or their lactone form.
• Preferred compositions according to the instant invention comprise a sophorolipid in which the ratio by weight of lactone form to acid form is in the range of 20:80 to 80:20, especially preferably in the ranges of 30:70 to 40:60.
• compositions for production of glucolipids can be carried out as described in WO2019154970.
• the present invention provides a composition preferably comprising as biosurfactant glucolipids, characterized in that the biosurfactant component A) comprises
• GL-C8C10 1 % by weight to 30% by weight, preferably 5% by weight to 25% by weight, particularly preferably 10% by weight to 20% by weight, of GL-C8C10, where the percentages by weight refer to the sum of all of the glucolipids present.
• composition comprises as biosurfactant glucolipids as described above with a content of 0.5% by weight to 20% by weight, preferably 2% by weight to 15% by weight, particularly preferably 3% by weight to 12% by weight, of GL-C10C12 where the percentages by weight refer to the sum of all of the glucolipids present.
• composition according to the invention is characterized in that the composition comprises as biosurfactant glucolipids as described above with a content of 1% by weight to 30% by weight, preferably 5% by weight to 25% by weight, particularly preferably 10% by weight to 20% by weight, of GL-C8C10,
• compositions according to the invention are characterized in that the composition comprises as biosurfactant glucolipids as described above with a content of 10% by weight to 20% by weight, of GL-C8C10, 5% by weight to 15% by weight, of GL-C10C12:1 ,
• a preferred composition according to the instant invention is characterized in that the biosurfactant is selected from rhamnolipids, sophorolipids and glucolipids.
• composition according to the instant invention comprises at least one sulfonic or sulfinic acid derivative of general formula (I); general formula (I) contains at least one chiral carbon atom.
• general formula (I) encompasses all possible enantiomers in context of the instant invention.
• composition according to the instant invention comprises at least one sulfonic or sulfinic acid derivative of general formula (I) in form of an enantiomer-mixture.
• composition according to the instant invention are present at least partially as salts on account of the given pH.
• the cations of the salts of the sulfonic or sulfinic acid derivative of general formula (I) present are selected from the group comprising, preferably consisting of, Li + , Na + , K + , Mg 2+ , Ca 2+ , Al 3+ , Zn 2+ , NH 4 + , primary ammonium ions, secondary ammonium ions, tertiary ammonium ions and quaternary ammonium ions, with Na + and K + being preferred, Na + being most preferred.
• a preferred composition according to the instant invention is characterized in that component A) is comprised in an amount of 5% by weight to 70% by weight, preferably 6% by weight to 60% by weight, particularly preferably 10% by weight to 55% by weight and especially preferably 20% by weight to 50% by weight, and component B) is comprised in an amount of 0.01% by weight to 10% by weight, preferably 0.1% by weight to 5% by weight, particularly preferably 0.2% by weight to 2% by weight, where the percentages by weight refer to the total composition.
• a preferred composition according to the instant invention is characterized in that the weight ratio of component A) to component B) is in the range of from 10 : 1 to 5000 : 1 , preferably from 20 : 1 to 1000 : 1 , more preferably from 25 : 1 to 250 : 1.
• R 1 selected from H and Ci - Ob alkyl
• compositions according to the invention can advantageously be incorporated into formulations, in particular in cosmetic formulations.
• compositions according to the invention for producing formulations, in particular cosmetic formulations, and also the formulations, in particular cosmetic formulations, which comprise the composition according to the invention.
• the formulation according to the invention preferably contains 0,5% by weight to 20% by weight, preferably 2% by weight to 15% by weight, particularly preferably 3% by weight to 12% by weight, of biosurfactants, where the percentages by weight refer to the overall formulation.
• preferred formulations according to the invention comprise at least - next to the biosurfactant - one further surfactant, it being possible to use, for example, anionic, nonionic, cationic and/or amphoteric surfactants.
• anionic, nonionic, cationic and/or amphoteric surfactants Preferably, from an applications-related point of view, preference is given to mixtures of anionic and nonionic surfactants.
• the total surfactant content of the formulation is preferably 5 to 60% by weight and particularly preferably 15 to 40% by weight, based on the total formulation.
• formulations according to the invention can comprise at least one additional component selected from the group of emollients, emulsifiers, thickeners/viscosity regulators/stabilizers,
• UV photoprotective filters antioxidants, hydrotropes (or polyols), solids and fillers, film formers, pearlescent additives, deodorant and antiperspirant active ingredients, insect repellents, self-tanning agents, preservatives, conditioners, perfumes, dyes, odour absorbers, cosmetic active ingredients, care additives, superfatting agents, solvents.
• Typical guide formulations for the respective applications are known prior art and are contained for example in the brochures of the manufacturers of the respective base materials and active ingredients. These existing formulations can generally be adopted unchanged. If required, however, the desired modifications can be undertaken without complication by means of simple experiments for the purposes of adaptation and optimization.
• compositions according to the invention and the formulations according to the invention comprising the composition according to the invention can advantageously be used for the cleaning of surfaces.
• the surface is preferably the surface of a living being, in particular of a person, with such surfaces particularly preferably being selected from skin and hair.
• the inventive use is a non-therapeutic use, preferably a cosmetic use.
• Figure 1 shows the discolouration over time for different rhamnolipid containing compositions.
• Rhamnolipids were prepared as described in EP3023431 and analysed.
• the proportion of rhamnolipids and salts thereof was > 90% by weight based on the dry mass.
• the relative proportions of the various rhamnolipid congeners in per cent by weight of the sum total of all rhamnolipids are given in the following table.
• the ratios refer to the acid form which is quantified in the HPLC analysis.
• Table 1 Composition of the rhamnolipids used. Data in % by weight of the respective congener (as acid form) based on the sum total of all rhamnolipids (as acid form).
• the protein content was determined by the photometric bicinchoninic assay (BCA assay, ThermaFisher Scientific) and was ⁇ 1 % by weight based on the dry mass of the rhamnolipid.
• sophorolipids REWOFERM ® SL ONE (Evonik) an aqueous solution of sophorolipids in lactone- and acid form was used.
• Glucolipids were prepared as described in example 2 of WO2019154970.
• Example 1 Odour panel for rhamnolipids containing the di-sodium salt of 2- hydroxysulfonatoacetate
• Test result is the sum of all point divided by the number of test persons. Additionally, the test persons assigned a ranking for all three samples.
• Example 2 Odour panel for rhamnolipids containing the zinc salt of 2-hydroxysulfonatoacetate
• test result is the sum of all point divided by the number of test persons. Additionally, the test persons assigned a ranking for all three samples.
• Example 3 Odour panel for sophorolipids containing the disodium salt of 2- hydroxysuifonatoacetate or the mixture of the zinc salts of 2-hydroxysulfinatoacetate, 2- hydroxysuifonatoacetate and sulfite
• the members of the test panel carried out the test in an "odour- neutral" room of a central lab.
• test result is the sum of all point divided by the number of test persons. Additionally, the test persons assigned a ranking for all three samples.
• Example 4 Colour preservation A 47.4 % aqueous rhamnolipid solution was used. The solution was stabilized with 12 ppm CIT/MIT (chloromethylisothiazolinone/methylisothiazolinone) against microbial growth and had a pH at 5.5. This solution was mixed with the di-sodium salt of 2-hydroxysulfonatoacetate (Blancolen HP, L. Briiggemann GmbH & CO KG) and the zinc salt of 2-hydroxysulfonatoacetate (TP1740, L. Briiggemann GmbH & CO KG) at concentrations of 0.1% and 0.5%. After the addition of the additives the pH was set to 5.6 with KOH. The mixture was incubated at 40°C under permanent stirring. In regular intervals the samples were analyzed on Gardner colour number up to 312 days.
• CIT/MIT chloromethylisothiazolinone/methylisothiazolinone
• Example 5 Odour panel for glucolipids containing the disodium salt of 2-hydroxysulfonatoacetate
• Three samples were prepared by using glucolipid material with a content of 49.2%. In the first sample no additive was used. In a second sample 2.0% of the disodium salt of 2- hydroxysulfonatoacetate (Blancolen HP, L. Briiggemann GmbH & CO KG) was added. In a third sample 0.5% of the disodium salt of 2-hydroxysulfonatoacetate (Blancolen HP, L. Briiggemann GmbH & CO KG) was used. The samples had a pH of 6.0. The samples were stored in the suitable test bottles at ambient temperature.
• test was carried out in an "odour-neutral" room of a central lab.
• test result is the sum of all point divided by the number of test persons. Additionally, the test persons assigned a ranking for all three samples.
• Example 6 Odour panel for glucolipids containing the disodium salt of 2-hydroxysulfonatoacetate, the zinc salt of 2-hydroxysulfonatoacetate or the zinc salts of 2-hydroxysulfinatoacetate, 2- hydroxysulfonatoacetate and sulfite at higher concentrations
• test was carried out in an "odour-neutral" room of a central lab.
• test result is the sum of all point divided by the number of test persons. Additionally, the test persons assigned a ranking for all three samples.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Birds (AREA)
• Epidemiology (AREA)
• Dermatology (AREA)
• Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Tropical Medicine & Parasitology (AREA)
• Cosmetics (AREA)

Priority Applications (4)

Applications Claiming Priority (2)

Publications (1)

Family

ID=75825473

Family Applications (1)

Country Status (5)

Cited By (5)

Citations (20)

Family Cites Families (3)

• 2022
  • 2022-04-28 US US18/558,976 patent/US20250073149A1/en active Pending
  • 2022-04-28 WO PCT/EP2022/061335 patent/WO2022233700A1/en not_active Ceased
  • 2022-04-28 CN CN202280033040.9A patent/CN117279613A/zh active Pending
  • 2022-04-28 JP JP2023568165A patent/JP2024517003A/ja active Pending
  • 2022-04-28 EP EP22726090.8A patent/EP4333797A1/en active Pending

Patent Citations (22)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events